Somaxon Sues Zydus Over Generic Silenor
The suit stems from an abbreviated new drug application Zydus filed seeking U.S. Food and Drug Administration approval to market generic versions of the 3-milligram and 6-milligram forms of Silenor, according to Somaxon. Silenor is a low-dose oral tablet formulation of the chemical doxepin, approved by the FDA for the treatment of insomnia.
Co-plaintiff ProCom One Inc. owns U.S....
To view the full article, register now.